Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Eisai Dividend Announcement
• Eisai announced a semi annually dividend of $0.52 per ordinary share which will be made payable on 2025-05-01. Ex dividend date: 2025-03-28
• Eisai's trailing twelve-month (TTM) dividend yield is 3.55%
• Eisai's payout ratio for the trailing twelve months (TTM) is 140.67%
Eisai Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-03-28 | $0.52 | semi annually | 2025-05-01 |
2024-09-27 | $0.55 | semi annually | 2024-11-19 |
2024-03-28 | $0.53 | semi annually | 2024-05-29 |
2023-09-28 | $0.54 | semi annually | 2023-11-17 |
2023-03-30 | $0.60 | semi annually | 2023-05-29 |
2022-09-29 | $0.56 | semi annually | 2022-11-18 |
2022-03-30 | $0.65 | semi annually | 2022-05-25 |
2021-09-29 | $0.72 | semi annually | 2021-11-19 |
2021-03-30 | $0.73 | semi annually | 2021-05-21 |
2020-09-29 | $0.76 | semi annually | 2020-11-19 |
2020-03-30 | $0.74 | semi annually | 2020-05-22 |
2019-09-27 | $0.74 | semi annually | 2019-11-19 |
2019-03-27 | $80.00 | semi annually | 2019-05-22 |
2018-09-26 | $0.62 | semi annually | 2018-11-19 |
2018-03-28 | $0.76 | semi annually | 2018-05-24 |
2017-09-27 | $0.62 | semi annually | 2017-11-17 |
2017-03-29 | $0.72 | semi annually | 2017-05-19 |
2016-09-28 | $70.00 | semi annually | |
2016-03-29 | $0.70 | semi annually | |
2015-09-28 | $0.58 | semi annually | |
2015-03-27 | $0.67 | semi annually | |
2014-09-26 | $0.64 | semi annually | |
2014-03-27 | $0.78 | semi annually |
Eisai Dividend per year
Eisai Dividend growth
Eisai Dividend Yield
Eisai current trailing twelve-month (TTM) dividend yield is 3.55%. Interested in purchasing Eisai stock? Use our calculator to estimate your expected dividend yield:
Eisai Financial Ratios
Eisai Dividend FAQ
Other factors to consider when evaluating Eisai as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Eisai stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Eisai's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Eisai publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Eisai distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Eisai are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Eisai sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Eisai distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Eisai declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Eisai's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Eisai's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.